Posted on September 10th, 2009 by Kelley Luckstein
Cytopia Limited's (ASX: CYT) Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various hematological disorders…
Preparations for the company's initial Phase I/II trial of CYT387 in patients
with myelofibrosis are currently being finalized. Myelofibrosis is a
life-threatening scarring of the bone marrow. This study will be undertaken at
the Mayo Clinic in Rochester Minnesota under the chairmanship of Dr. Ayalew
Tefferi, a key opinion leader in MPD treatment. The company anticipates
opening the study to enrolment in the fourth quarter of 2009. Further details
of the study will be disclosed following site ethics committee approval.
You must be logged-in to the site to post a comment.